Authoritative medical journals confirm!

The Delta mutant strain of the new coronavirus (B.

Today, the New England Journal of Medicine (NEJM) recently published a real-world study from Public Health England.

In this real-world study, the research team evaluated the effectiveness of different new crown vaccines against Delta mutant strains in causing symptomatic new crown virus disease (COVID-19) based on data from the period when the Delta mutant strain began to circulate and as of mid-May.

Through data statistics, a total of 19109 symptomatic cases ≥16 years of age were included.

Analysis of the effectiveness of the vaccine showed that the two doses of the vaccine showed high protection against the Delta mutant strain

In contrast, the data also suggests the importance of complete vaccination

In addition, the study also observed the protective effect of another new crown vaccine ChAdOx1 nCoV-19 on the Delta mutant strain

Similarly, when only one dose is inoculated, the protective effect gap is more obvious

Based on these data, the research team concluded that after two doses of BNT162b2 or ChAdOx1 nCoV-19 vaccine, there was only a "modest difference" in the effectiveness of the Delta mutant strain compared with the Alpha mutant strain

The paper pointed out that this analysis has benefited from large-scale case sequencing and the tracking of vaccination data in the United Kingdom

The research team also stated that this study has certain limitations.

But overall, real-world data indicate that the two doses of vaccine have a high level of vaccine efficacy in preventing symptomatic diseases caused by the Delta mutant strain

Note: The original text has been deleted

Reference

[1] Jamie Lopez Bernal, et al.